VERA
Vera Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$36.99-3.92%
Price as of Jul 20, 2026
VERA financials
Vera Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | -$846.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $846.0K |
| Operating expenses | $315.5M | $167.2M | $102.0M | $91.7M |
| Operating income | -$315.5M | -$167.2M | -$102.0M | -$90.9M |
| Net income | -$299.6M | -$152.1M | -$96.0M | -$89.1M |
| EBITDA | -$291.6M | -$144.4M | -$92.2M | -$88.9M |
| Basic EPS | $-4.66 | $-2.75 | $-2.25 | $-3.35 |
| Diluted EPS | $-4.66 | $-2.75 | $-2.25 | $-3.35 |
| Balance sheet | ||||
| Cash & equivalents | $354.7M | $92.6M | $45.7M | $43.5M |
| Total assets | $734.7M | $655.7M | $175.5M | $131.4M |
| Total liabilities | $130.2M | $78.5M | $73.9M | $54.5M |
| Stockholders’ equity | $604.5M | $577.2M | $101.7M | $76.9M |
| Total debt | $77.3M | $54.6M | $53.7M | $31.3M |
| Net debt | -$277.4M | -$38.0M | $8.0M | -$12.2M |
| Cash flow | ||||
| Operating cash flow | -$241.1M | -$134.7M | -$92.2M | -$67.6M |
| Capital expenditure | -$630.0K | -$972.0K | -$63.0K | -$62.0K |
| Free cash flow | -$241.7M | -$135.7M | -$92.2M | -$67.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | -$13.0K | $0.00 | $0.00 |